Innospera
innospera.com
Actively hiring
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
Anges Québec
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
Anges Québec Investors in similar startupsfunds that back the companies most like this one
backs Neurogastrx
backs AAVantgarde
Similar startupsby what they do, their industry and backers
Clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS).
Neurogastrx, Inc.. Thank you for visiting the website for Neurogastrx, Inc. ("Company"), a privately held, late clinical-stage…
Oak Hill Bio is a clinical-stage biotechnology company focused on acquiring and developing outstanding rare disease drugs that have been…
Immunotherapiesfor fibrotic disease. Neotis is designing therapies that direct the immune system to eliminate cells driving fibrotic…
AAVantgarde is a clinical-stage biotechnology company developing next-generation therapies for inherited retinal diseases with high unmet…
About Us Proniras Corporation ("Proniras") is a clinical-stage biotechnology company focused on the development of novel small-molecule…
News
Innospera Pharma ernennt Dr. Glenn Crater zum Chief Medical Officer zur Unterstützung der klinische
Innospera Pharma Inc. ("Innospera
Read more
Report
Innospera Pharma nomina il dott. Glenn Crater in qualità di Chief Medical Officer per fornire supporto allo sviluppo verso la fase clinica di ING-006 - Business Wire - Ansa.it
(ANSA)
Read more
Report
Innospera Pharma Inc.: Innospera Pharma ernennt Dr. Glenn Crater zum Chief Medical Officer zur Unterstützung der klinischen Entwicklung von ING-006
Innospera Pharma Inc. ("Innospera"), ein privates Biotechnologieunternehmen im fortgeschrittenen klinischen Stadium, das differenzierte niedermolekulare Modulatoren von GPR84 und GPR40 zur Behandlung
Read more
Report
Innospera Pharma ernennt Dr. Glenn Crater zum Chief Medical Officer zur Unterstützung der klinischen Entwicklung von ING-006
Read more
Report
Innospera Pharma Appoints Dr. Glenn Crater as Chief Medical Officer to Support Advancement of ING-006 Toward the Clinic
MONTREAL, June 09, 2025--Innospera Pharma appoints Dr. Glenn Crater as Chief Medical Officer to support advancement of ING-006 toward the clinic
Read more
Report
Innospera Pharma Inc.: Innospera Pharma Appoints Dr. Glenn Crater as Chief Medical Officer to Support Advancement of ING-006 Toward the Clinic
Innospera Pharma Inc. ("Innospera"), a private, near-clinical-stage biotechnology company advancing differentiated small molecule modulators of GPR84 and GPR40 to treat inflammatory and metabolic diseases
Read more
Report
Innospera Pharma nomme Dr Glenn Crater Chef de la direction médicale afin de contribuer à l'avancement du ING-006 au stade clinique
Read more
Report
François Ravenelle, PhD, zum Präsidenten und CEO von Innospera Pharma ernannt, um die nächste Wachstumsphase zu leiten
Read more
Report